(Reuters) - AstraZeneca (AZN.L) on Tuesday received $23.7 million in funding from a U.S. government agency to advance the development of antibody-based COVID-19 treatments as the British drugmaker ramps up efforts beyond its potential vaccine to combat the pandemic.
from Opinions and Editorials » Manila Bulletin News
Read The Rest...
Posting Komentar